Mural Oncology Presents Data Across Its Pipeline At 39th SITC Annual Meeting
Mural Oncology Presents Data Across Its Pipeline At 39th SITC Annual Meeting
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
在部分愛文思控股實體瘤患者中，尼威勒肽的較少頻繁靜脈注射方案顯示出以卵巢癌和粘膜黑色素瘤爲特定靶點的藥效活性和免疫激活
Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing pursuit of IND-enabling studies with candidate nomination anticipated by the end of 2024, and IND submission expected in Q4 2025
臨床前數據顯示通過Mural的IL-18變體可產生持久的免疫應答和抑制腫瘤生長，進一步加強了對即將在2024年年底前提名候選藥物的IND啓動研究的追求，IND提交預計在2025年第四季度進行
Additional preclinical data from Mural's IL-12 program suggest the company's approach may unlock the potential of IL-12 as a therapeutic by mitigating the cytokine's historic toxicity; company continues to expect candidate nomination by the end of 2024
來自Mural的IL-12項目的額外臨床前數據表明公司的方法可能通過緩解細胞因子的歷史毒性來釋放IL-12的潛力，公司仍期望在2024年年底前提名候選藥物
